QR-Code

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

Abstract Background Colorectal cancer (CRC) is a heterogeneous disease with a complex biology and a wide number of altered genes such as BRAF, KRAS and PIK3CA. Advances with new-targeted therapies have been achieved and available treating options have prolonged patient’s survival. However, BRAF-muta...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Evelina Miele, Luana Abballe, Gian Paolo Spinelli, Zein Mersini Besharat, Giuseppina Catanzaro, Martina Chiacchiarini, Alessandra Vacca, Agnese Po, Carlo Capalbo, Elisabetta Ferretti
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2020-02-01
Schriftenreihe:BMC Cancer
Schlagworte:
BRAFV600E mutation
Colon cancer
Molecular therapy
Afatinib
Vemurafenib
ErbB2
Online-Zugang:http://link.springer.com/article/10.1186/s12885-020-6586-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge